Team:British Columbia/Human Practices

From 2012.igem.org

(Difference between revisions)
m
Line 5: Line 5:
==Intellectual Property==
==Intellectual Property==
[https://2012.igem.org/Team:British_Columbia/Human_Practices/FAQ FAQ]
[https://2012.igem.org/Team:British_Columbia/Human_Practices/FAQ FAQ]
-
*[https://docs.google.com/spreadsheet/ccc?key=0AngNayWeH_rTdHdMb09iNDNaYV95TllLazFNTmdCQlE Survey] for other teams
+
*IP [https://docs.google.com/spreadsheet/ccc?key=0AngNayWeH_rTdHdMb09iNDNaYV95TllLazFNTmdCQlE Survey]
 +
*IP Survey [https://docs.google.com/spreadsheet/ccc?key=0AngNayWeH_rTdC1QTTVoXzdHc0pZY0RxTFBOcy1Bb1E Results]
**Edit the form by going to Form -> Edit form
**Edit the form by going to Form -> Edit form
*Professionals to Consult
*Professionals to Consult

Revision as of 01:21, 25 September 2012

British Columbia - 2012.igem.org


Contents

Intellectual Property

FAQ

  • IP Survey
  • IP Survey Results
    • Edit the form by going to Form -> Edit form
  • Professionals to Consult
    • Ask UBC [http://www.uilo.ubc.ca tech transfer office]
      • Mike Gold suggested dropping his name to Ian Bell, Technology Transfer Manager for the Life Sciences
    • Dr. Andre Marziali, EngPhys Director
    • OSLI?
  • [http://biobricks.org/bpa/faq/ biobrick agreement]

Previous iGEM work

2011 UQ-australia [http://classic.the-scientist.com/blog/display/53835/ 2010 The Scientist Article] 2010 Caltech [http://igem.uwaterloo.ca/share/Outreach/Human%20Practices%202010/Role%20of%20Biotech%20IPR%20in%202030.pdf 2010 Waterloo] 2007 Edinburgh 2008 UCSF

Community Outreach

OSLI feedback

  • Biosafety
  • Efficiency
  • Environmental